See more : Consórcio Alfa de Administração S.A. (BRGE5.SA) Income Statement Analysis – Financial Results
Complete financial analysis of 180 Life Sciences Corp. (ATNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 180 Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sonel S.A. (SON.WA) Income Statement Analysis – Financial Results
- Post Holdings, Inc. (0KJZ.L) Income Statement Analysis – Financial Results
- USHG Acquisition Corp. (HUGS-UN) Income Statement Analysis – Financial Results
- Ford Motor Company 6.20% Notes (F-PB) Income Statement Analysis – Financial Results
- S.T. Corporation (4951.T) Income Statement Analysis – Financial Results
180 Life Sciences Corp. (ATNF)
About 180 Life Sciences Corp.
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 0.00 | 0.00 |
| Gross Profit | -105.68K | -109.00K | -116.30K | -125.33K | -72.24K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.78M | 2.43M | 3.95M | 2.29M | 2.04M | 1.07M | 0.00 |
| General & Administrative | 10.69M | 15.47M | 11.69M | 3.32M | 5.89M | 7.67M | 343.88K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 38.83K | 12.96M | 0.00 | 0.00 |
| SG&A | 10.69M | 15.47M | 11.69M | 3.36M | 18.85M | 7.67M | 343.88K |
| Other Expenses | 0.00 | 246.34B | 770.60K | 264.74K | 250.40K | 0.00 | 0.00 |
| Operating Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Cost & Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Interest Income | 0.00 | 26.67K | 186.21K | 1.09M | 181.41K | 12.24K | 663.02K |
| Interest Expense | 44.83 | 26.67K | 186.21K | 1.09M | 185.14K | 0.00 | 0.00 |
| Depreciation & Amortization | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 23.08K | 52.52K |
| EBITDA | -22.13M | -17.79M | -20.05M | -5.52M | -20.79M | -8.72M | -343.88K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.48M | -17.90M | -15.64M | -5.65M | -20.86M | -8.74M | -343.88K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.81M | -21.77M | -4.71M | -5.26M | -4.54M | -5.75M | 663.02K |
| Income Before Tax | -22.28M | -39.67M | -20.35M | -10.90M | -25.40M | -14.50M | 319.13K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.35M | 942.75K | 23.20K | 20.43K | 9.50K | -1.00 | 195.37K |
| Net Income | -19.94M | -38.73M | -20.32M | -12.01M | -25.39M | -14.50M | 123.76K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -52.60 | -387.26 | -247.86 | -255.46 | -875.66 | -1.45K | 12.38 |
| EPS Diluted | -52.59 | -387.18 | -246.32 | -251.32 | -874.45 | -1.45K | 12.38 |
| Weighted Avg Shares Out | 379.00K | 100.00K | 82.00K | 47.00K | 29.00K | 10.00K | 10.00K |
| Weighted Avg Shares Out (Dil) | 379.09K | 100.02K | 82.51K | 47.77K | 29.04K | 10.00K | 10.00K |
180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors
PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of...
180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately.
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Officer, Blair Jordan. Dear Stockholders: We are excited to announce...
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
PALO ALTO, CA / ACCESSWIRE / October 9, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180"), is pleased to announce that it has received confirmation from Nasdaq that the Company has officially regained compliance with Nasdaq Listing...
180 Life Sciences Corp. - Corporate Updates
Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance Sheet PALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide...
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a...
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced topline results from a clinical pharmacology study (the...
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock...
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”)...
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a...
Source: https://incomestatements.info
Category: Stock Reports